Immunofluorescence assay identified that BRD9 was highly expressed in most cancer cell lines, such as epidermoid carcinoma cell line A‐431, human osteosarcoma cell line U‐2 OS, human glioblastoma cell line U‐251 MG, human ovarian carcinoma cell line EFO‐21 and squamous cell carcinoma cell line SiHa (Figure 2D). Here, BRD9 is linked to ovarian carcinoma.